Savara

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. 

CEO
Matthew Pauls
CEOMatthew Pauls
Employees
70
Employees70
Headquarters
Langhorne, Pennsylvania
HeadquartersLanghorne, Pennsylvania
Founded
1995
Founded1995
Employees
70
Employees70

SVRA Key Statistics

Market cap
990.32M
Market cap990.32M
Price-Earnings ratio
-8.36
Price-Earnings ratio-8.36
Dividend yield
—
Dividend yield—
Average volume
2.56M
Average volume2.56M
High today
$4.97
High today$4.97
Low today
$4.75
Low today$4.75
Open price
$4.94
Open price$4.94
Volume
1.41M
Volume1.41M
52 Week high
$7.01
52 Week high$7.01
52 Week low
$3.86
52 Week low$3.86

Stock Snapshot

As of today, Savara(SVRA) shares are valued at $4.87. The company's market cap stands at 990.32M, with a P/E ratio of -8.36.

As of 2026-10-31, Savara(SVRA) stock has fluctuated between $4.75 and $4.97. The current price stands at $4.87, placing the stock +2.5% above today's low and -2.0% off the high.

The Savara(SVRA)'s current trading volume is 1.41M, compared to an average daily volume of 2.56M.

In the last year, Savara(SVRA) shares hit a 52-week high of $7.01 and a 52-week low of $3.86.

In the last year, Savara(SVRA) shares hit a 52-week high of $7.01 and a 52-week low of $3.86.

SVRA News

Simply Wall St 1d
Discovering 3 Intriguing Penny Stocks With Market Caps Over $300M

The market has been flat in the last week, but it is up 10% over the past year with earnings forecast to grow by 17% annually. For those looking to invest in sm...

Simply Wall St 2d
Molgramostim Trial Update Might Change The Case For Investing In Savara

Savara Inc. recently presented a post-hoc IMPALA trial analysis at CHEST 2026, highlighting molgramostim outcomes in aPAP patients with baseline DLco% above 70%...

Simply Wall St 4d
Savara Jumped, But What Is Behind The Fresh Attention?

Advertisement Savara’s CHEST 2026 data and what it means for investors Savara (SVRA) is back on investors’ radars after presenting new poster data from its IM...

Analyst ratings

100%

of 9 ratings
Buy
100%
Hold
0%
Sell
0%

More SVRA News

TipRanks 5d
Strong Specialist Support for MOLBREEVI, Broad aPAP Opportunity Underpin Fein’s Unchanged $10 Price Target and Buy Rating

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Savara. The associated price target remains the same with $10.00. Andrew Fein has gi...

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.